Synthesis and cytotoxic evaluation of some substituted 5-pyrazolones and their urea derivatives

Article abstract of DOI:10.3390/molecules25040900

In this paper, a series of new substituted-5-pyrazolones were first synthesized, then formulated by the Vilsmeier–Haack reaction to obtain substituted-4-carbaldehyde-5-pyrazolones. In the final step, when urea was reacted with formulated pyrazolones, we found that, instead of the C=N bond in azomethine form, the compounds tautomerized to form a series of novel pyrazole-4ylidenemethylurea structures. The structures of these compounds were elucidated by FTIR, ¹H, ¹³C NMR, LC-MS/MS, and elemental analysis methods. The cytotoxic and antioxidant effects of substituted 5-pyrazolones and their pyrazolone-urea derivatives were investigated in metastatic A431 and noncancerous HaCaT human keratinocytes by a mitochondrial activity test. The effects of the compounds on the migration of cancerous and noncancerous cell lines were investigated by using a cell scratch assay. The General Linear Model, Statistical Package for Social Sciences (SPSS v26) was used to determine if there was a statistically significant difference between the control and the treatment groups. Four of the nine compounds showed an antioxidant effect. All 5-pyrazolone-urea compounds showed higher toxicity (p < 0.05) in cancerous A431 cells compared to noncancerous cells at all time points. All compounds also showed a biphasic hormetic effect. Four of the nine compounds inhibited cell migration.

Full text of DOI:10.3390/molecules25040900

molecules
Article
Synthesis and Cytotoxic Evaluation of Some
Substituted 5-Pyrazolones and Their Urea Derivatives
Aliye Gediz Erturk * and Hilal Omerustaoglu
Department of Chemistry, Faculty of Science & Arts, Ordu University, 52200 Ordu, Turkey;
hilal_ustaoglu@hotmail.com
* Correspondence: aliyeerturk@gmail.com; Tel.: +90-530-553-1076
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 17 January 2020; Accepted: 15 February 2020; Published: 18 February 2020
Abstract: In this paper, a series of new substituted-5-pyrazolones were first synthesized, then
formulated by the Vilsmeier–Haack reaction to obtain substituted-4-carbaldehyde-5-pyrazolones.
In the final step, when urea was reacted with formulated pyrazolones, we found that, instead
of the C=N bond in azomethine form, the compounds tautomerized to form a series of novel
pyrazole-4-ylidenemethylurea structures. The structures of these compounds were elucidated by
FTIR, 1H, 13C NMR, LC-MS/MS, and elemental analysis methods. The cytotoxic and antioxidant
effects of substituted 5-pyrazolones and their pyrazolone-urea derivatives were investigated in
metastatic A431 and noncancerous HaCaT human keratinocytes by a mitochondrial activity test. The
effects of the compounds on the migration of cancerous and noncancerous cell lines were investigated
by using a cell scratch assay. The General Linear Model, Statistical Package for Social Sciences (SPSS
v26) was used to determine if there was a statistically significant difference between the control and the
treatment groups. Four of the nine compounds showed an antioxidant effect. All 5-pyrazolone-urea
compounds showed higher toxicity (p < 0.05) in cancerous A431 cells compared to noncancerous
cells at all time points. All compounds also showed a biphasic hormetic effect. Four of the nine
compounds inhibited cell migration.
Keywords: 5-pyrazolone; urea derivatives; cell proliferation; antioxidant activity
1. Introduction
The 5-pyrazolones are used for industrial purposes in the forms of metal extraction agents [
anticorrosive components [ ], and thermally stable polymers [ ]. Besides, they are used in
pharmaceutical chemistry for drug development [ ]. Some of their pharmacological uses include
analgesic, anti-inflammatory, antipyretic, antiparasitic, antimalarial, and antifungal effects [ ]. Some
5-pyrazolones inhibit enzyme activity that causes neurodegenerative effects [ ], and others are used as
1],
2
3
4
5
6
sedatives. In agricultural industries, they are used as pesticides against insects and weeds [7,8].
In particular, when halogenated derivatives of pyrazolones are considered, 4,4-dichloro-
5-pyrazolone derivatives (
derivatives (II) are important cytotoxic agents for the treatment of tumor metastasis. They also
offer potential options for treating AIDS, diabetes, and autoimmune diseases [ ]. While indole-derived
I) are human telomerase inhibitors, while 4,4-dibromo-5-pyrazolone
9
5-pyrazolones (III) have also been indicated to be a potential anticancer agent in the treatment of lung
cancer [10], edaravone (IV) has been shown to exhibit a neuroprotective activity to prevent ischemic
(brain, myocardial) paralysis due to its antioxidant properties (Scheme 1) [11].
Molecules 2020, 25, 900; doi:10.3390/molecules25040900
www.mdpi.com/journal/molecules

Molecules 2020, 25, 900
2 of 20
Scheme 1. Some biologically active 5-pyrazolone derivatives.
The purpose of this research was to (1) synthesize new structures that have a pyrazolone building
block (or core), which may also be essential starting materials that support the development of the
pyrazolone library, and (2) investigate the biological potential of these newly synthesized structures,
which have strong pharmacologic properties and reduced side effects.
Therefore, pyrazolones, which are obtained from the reactions of suitably substituted β-keto esters
and substituted hydrazines, were formulated by the Vilsmeier–Haack reaction. Next, they were entered
into a reaction with urea, which resulted in the synthesis of novel urea-pyrazolone derivatives. The
biopotential of these compounds was investigated by using three approaches. First, the cytotoxic effects
of these compounds on A431 malignant keratinocytes and noncancerous immortal HaCaT keratinocytes
were evaluated by using a colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) cell viability assay. Second, the antioxidant potential of these compounds on the prevention of
cell death caused by hydrogen peroxide was investigated. Third, the effects of these compounds on
cell migration were investigated by using a cell scratch assay on cancerous and noncancerous A431
and HaCaT cell lines.
2. Results and Discussion
2.1. Chemistry
The first four (3a
obtained from the reflux of phenylhydrazine with glacial acetic acid in an oil bath with
the appropriate -keto ester [ ]. Only minor changes were present in the work-up part of
3-(4-nitrophenyl)-1-phenyl-1H-pyrazole-5(4H)-one 3d 12]. The remaining four 5-pyrazolone
compounds (3d ) were obtained from the reaction of the appropriate -keto esters with
–d) of the eight synthesized 5-pyrazolone compounds (3a–h) were
β
9
[
–
h
β
phenylhydrazine hydrochloride in different reaction conditions (ethanol, at room temperature for 3h
methanol reflux for (3d–3g)) (Scheme 2).
,
Scheme 2. Synthesis of 5-pyrazolone compounds (3a–h).

Molecules 2020, 25, 900
3 of 20
Furthermore, the compound 3h has been previously described in the literature as an
oily, yellow product of a reaction between p-bromophenyl hydrazine and 2,2-difluoro-4-alkoxy-
1,3,2-dioxaborinane [13]. The spectral data of the compound obtained in solid state in this study, under
much more mild conditions, were also consistent with the results of this study.
The 4-formyl-5-pyrazolone derivatives (4a–d) were synthesized by transferring the formyl group to
the resulting 5-pyrazolone nuclei under Vilsmeier conditions and were provided with excess phosphorus
oxychloride and N,N-dimethylformamide (Scheme 3). In the final step, these four aldehydes were
reacted with excess urea in N,N-dimethylformamide (DMF) to give the desired ureamethylidene
derivatives of pyrazolones (Scheme 3). Of these, the compound 4a was previously synthesized by
Porai and coworkers [14] by mixing 1-phenyl-3-methyl-4-hydroxymethylene-5-pyrazolone and urea in
benzene. Crystallization and column chromatography methods, in different solvent systems, were
applied to purify all compounds. All spectral data presented for characterization of these newly
synthesized compounds (elemental analysis, FTIR, 1H and 13C NMR, and LC-MS/MS methods) were
in agreement with each other.
Scheme 3. Synthesis of 4-formyl-5-pyrazolones (4a–d) and 5-pyrazolone-urea compounds (5a–d).
2.2. FTIR
The IR spectra (Figures S1–S9 in Supplementary Materials) of the newly synthesized of pyrazolone
compounds (3e–h) confirmed the chemical identity of the derivatives. Furthermore, the broad bands
between 2681 and 2441 cm1 and the absence of any signal attributable to carbonyl stretching vibration
proved that 3e and 3h mainly existed in enol form due to intramolecular chelation by hydrogen bonds
in a solid state (Scheme 2).
In the pyrazolone-urea derivatives, the doublet peak between 3421–3294 and 3278–3124 cm−1 was
determined as the stretching peaks of –NH2 group, between 3201–3190 cm−1 to single peak as the
stretching of urea -NH group, between 1759–1662 cm−1 as the stretch peak of pyrazolone carbonyl,
and between 1673–1643 cm−1 as the stretch peak of urea carbonyl.
2.3. NMR
In the 1H-NMR spectra taken in CDCl3 of (3f
–h) compounds, -CH2 signals of the pyrazolone
ring respectively gave resonance at 3.92 ppm (for 3f and 3g) and 3.42 ppm (for 3h) as singlets (Figures
S11–S13 in Supplementary Materials). In the literature on tautomeric forms of 5-pyrazolones, it is
stated that they can exist in three main tautomeric structures. The research indicates that the form
which will be more dominant depends mainly on the solvent. In the gaseous phase, apolar solvent
and solvents with low polarity, such as CHCl3, CH2Cl2, and CCl4, only the CH form is observed. In
polar aprotic solvents, such as DMSO, THF, and CH3CN, the mixture of OH and NH structures having
a dynamic equilibrium with each other is predominant as the main form [15,16]. The formation of
these forms is dependent on specific solvation effects and electrostatic interactions between solvent

Molecules 2020, 25, 900
4 of 20
and solute. If there is a structure supporting the hydrogen bond acceptor near the hydroxyl group, the
OH form is observed, and the structure is stabilized by the in-molecule O–H . . . O bonds [17]. The
compound 3h synthesized has a clear -CH2 signal in the pyrazolone ring, especially in proton NMR,
and the absence of a broad peak of 10–12 ppm OH proton in 1H-NMR confirms that the balance shifts
to CH form in CDCl3 (Scheme 4).
Scheme 4. Tautomeric form of the compound 3h in CDCl3.
The 1H-NMR spectrum obtained in DMSO-d6 of compound 3e contained an OH tautomer. This
was confirmed by the presence of pyrazolone proton at 6.20 ppm and hydroxy proton
δ at 12.01 ppm
(Figure S10). In the 1H-NMR spectrum of compound 4d, the peak at
δ
10.10 ppm confirmed that the
formyl group was attached to the C4 carbon of the starting compound, the pyrazolone ring. This peak
confirmed that the formyl group was attached to the C4 carbon of the pyrazolone ring of the starting
compound (Figure S14). Besides, the presence of the OH peak of the hydroxyl proton at 9.90 ppm
showed that this compound had the OH tautomeric structure.
1
When the H-NMR of the pyrazolone-urea derivatives (5a
–
d) were examined, a proton-NH
signaling doublet at 11.1–9.69 ppm in the downfield of the spectrum, a proton-CH signaling doublet
at 8.31–8.18 ppm, at 9.47–7.79 ppm -NH2 signals, which resonated in the form of small broad peaks,
were observed. Amarasekara and coworkers [18] stated that Schiff-based derivatives prepared from
4-acetyl-5-methyl-2-phenyl-2,4-dihydro-pyrazole-3-one compounds with alkyl amines are present
in the tautomeric form of amine-one (
I) in chloroform in NMR. Pyrazolones and 4-acylpyrazolones
are known to exhibit interesting keto-enol tautomerism, and in principle, Schiff-based derivatives of
4-acylpyrazolones may exist in five possible tautomeric forms, imine-ol, imine-one (I), imine-one (II),
amine-one (I), and amine-on (II) (Scheme 5).
Scheme 5. Tautomeric forms of Schiff-based derivatives of 4-acylpyrazolones [18].
The synthesized pyrazolone-urea compounds (5a–5d) had the –NH. The amino (-NH2) and
carbonyl (C=O) vibration mode bands were seen in the IR spectrum, and the -NH, -NH2, and -CH
peaks seen in the 1H-NMR showed not to prefer the imine-one form of the pyrazolone ring. This
supports the presence of the amine-one tautomeric form, where the urea molecule was attached to the
carbon C4 as C = C bond (Scheme 6).

Molecules 2020, 25, 900
5 of 20
Scheme 6. Tautomerism of synthesized compounds (5a–d).
In the 13C spectra for (3f
–h) of the pyrazolone compounds (Figures S19–S27 in Supplementary
Materials), the -CH2 (C4 carbon) carbon of the pyrazolone ring resonated at 43.1 ppm (for
3f) and 39.32 ppm (for 3g and 3h). The pyrazolone carbonyl (C=O pyrazolone) resonated
at 170.5 ppm for compound 3f, and at 169.7 ppm for compounds 3g and 3h
.
These signals
showed us that all three pyrazolones were compatible with the form -CH2. Our results were
found to be compatible with the spectral values of 3h yellow oily compound obtained by
reaction of 2,2-difluoro-4-alkoxy-1,3,2-dioxaborinane with p-bromophenyl hydrazine, as reported by
Stefane and coworkers [13]. Ragab and coworkers [8], in their studies involving the synthesis
of 4-substituted-1H-pyrazole-5 (4H)-one, 1-(4-chlorophenyl)-3-phenyl-1H-pyrazole-5(4H)-one in
13C-NMR spectrum, showed the C5 carbon, to which the enolic OH group is attached, at 154
ppm. Similarly, the compound 3e synthesized in the pyrazolone ring that was linked to the hydroxy
group C5 carbon resonated at 154.5 ppm, while the C4 carbon of the pyrazolone ring resonated at 86.5
ppm, and the C3 carbon resonated at 147.7 ppm.
The 13C spectrum of compound 4d, which was a formulated pyrazolone, pointed to the aldehyde
group attached from the fourth carbon to the peak pyrazolone ring, which was resonant at 183 ppm. In
the pyrazolone ring, the C5 carbon, to which the hydroxy group was attached, resonated at 150.9 ppm,
while the C4 carbon of the pyrazolone ring resonated at 116.8 ppm.
For the urea compounds (5a–d
), in the 13C spectra, signals that belonged to the C4 carbon, to which
the urea molecule was attached, were seen at 104.8–91.73 ppm, while the pyrazolone carbonyls were
seen at 165.8–164.5 ppm (C=O pyrazolone), and the resonances of urea carbonyls in the compounds
were observed at 157.8–152.9 ppm. The NH-CH carbons in the compounds also peaked at 139.2–138.8
ppm. Besides this, our results were found to be consistent with the spectral values of compound
5a obtained by the reaction of urea with edaravone in benzene, as reported by Porai-Koshits and
coworkers [14].
2.4. Biological Activity of Compounds
The role of reactive oxygen species (ROS) in cancer initiation, promotion, and progression is well
documented [19]. ROS induce mutations by causing the oxidation of DNA via Fenton reactions [20,21].
Antioxidants stabilize the free radicals, thus preventing the mutations that result from the damage,
which may lead to cancer [22]. Previous studies have also reported that some pyrazole derivatives
might prevent metastasis because of their potential as anti-angiogenesis agents [23]. Because of these
reports, the cytotoxic, antioxidant, and antimetastatic potential of the compounds were tested. The
antimetastatic potential of the compounds was tested by using cell scratch assay. In order to assure
that the wound closure was due to cell migration and not cell proliferation, we serum-starved the cells
for 24 h before wounds were created.
Furthermore, 2 µg/mL colcemid was added to the medium to inhibit cell proliferation. To
minimize the cytotoxic effects of compounds on cell migration, cells were treated with 1 mM compound.
None of the tested compounds showed a cytotoxic effect on the viability of A431 and HaCaT cells at
this concentration.
2.4.1. Effects of Compounds on Cell Viability
To examine the impact of compounds on the viability of cancerous vs. noncancerous cells, we
exposed the A431 metastatic skin cancer cells and HaCaT immortalized noncancerous skin cells to

Molecules 2020, 25, 900
6 of 20
seven concentrations (0.001, 0.005, 0.01, 0.05, 0.1, 0.5, and 1 mM) of each of the compounds for 24, 48,
72, and 96 h (Figures S37–S46 in Supplementary Materials). Control group received only vehicle (0.1%
DMSO). The cytotoxic effect of compounds was measured by using methyl thiazole tetrazolium (MTT)
assay, which measures cell viability and proliferation based on the reduction of MTT to formazan.
Statistical analyses of the effects of the compounds on cell viability were determined using a The
General Linear Model, Statistical Package for Social Sciences (SPSS v26).
All compounds containing urea (5a–d) showed higher toxicity (p < 0.05) to cancerous A431 cells
when compared to the noncancerous cells at all time points (except for 5b at 48 h and 5d at 96 h).
Compounds (5a–d) also showed a biphasic response (hormesis). Exposure to low concentrations
caused an increase in cell viability, whereas high concentrations reduced cell viability (p < 0.05). The
degree of biphasic dose response varied for different compounds (Figures S42–S45).
Compound 5a reduced cell viability of cancerous A431 cells by 80% at higher concentrations
(0.5 mM and higher). This proved that Compound 5a was selectively toxic to the cancerous cells as
it showed minimal toxicity (10%) to noncancerous HaCaT cells under the same conditions (Figure
S42). The cytotoxic effect of 5b was higher on cancerous A431 cells. As the treatment time and dose
increased, the cytotoxic effect increased in both cell lines (p < 0.05). After 24 h of treatment, compound
5b showed a hormetic effect on HaCaT cells, whereas it did not cause any increase in viability of
cancerous A431 cells at high concentrations (Figure 1).
Figure 1. Effect of 5b on cell viability of cancerous vs. noncancerous cells at 24 h.
Compound 5c also showed a higher toxicity level to cancerous cells (p < 0.05), particularly when
treated with high concentrations. Toxicity of 5c was also time-dependent. Longer treatment times
increase toxicity showing that the compound was stable in cell culture media for 76 h (Figure 2).
Figure 2. Effect of 5c on cell viability of cancerous vs. noncancerous cells at 24 h (left), 48 h (right).
Compound 5d (Figure S45) lost its toxic effect after 24 h of treatment, which demonstrated that
the compound might be unstable in solution.
Compounds 3e and 3f showed hormesis at low concentrations. A dose- (p < 0.05) and time-
dependent (p < 0.05) increase in the cytotoxic effect was observed for cancerous A431. Both compounds
showed lower toxicity to HaCaT cells (Figure S37 and S38).

Molecules 2020, 25, 900
7 of 20
All of the seven compounds discussed above had differential toxicity to cancerous cells (p < 0.05)
and low toxicity to noncancerous cells. Drugs that were selectively toxic to cancerous cells were highly
sought after since nonselective drugs cause a deleterious effect on healthy human cells. Therefore,
we plan to conduct further investigations to discover the biochemistry of this selective toxicity. This
is not only significant for uncovering the pharmaceutical potential of these compounds, but also an
understanding of the bases for this selective toxicity can provide invaluable insights to researchers. It
will help researchers to develop drugs that are highly toxic to tumor cells while they are minimally
toxic to the healthy cells.
Compounds 3h and 4d caused time- and dose-dependent cytotoxic effects (p < 0.05), both in
cancerous and noncancerous cells (Figure 3). Even though they had differential cytotoxicity (p <
0.05), their cytotoxic effect was higher to noncancerous cells when compared to the cancerous cells.
Compound 3g caused a nearly 100% toxicity to both cancerous and noncancerous cell lines at 96 h and
high concentrations (p < 0.05). Because compounds 4d and 3g showed higher toxicities to HaCaT cells,
we speculate that their potential applicability for pharmaceutical uses is limited.
Figure 3. Effect of 3h on cell viability of cancerous vs. noncancerous cells at 24 h.
Recent research shows that pyrazole derivatives show cytotoxic effects on a variety of cell lines via
several different biochemical mechanisms. For example, ferrocenyl pyrazole derivatives were reported
to inhibit phosphoinositide 3-kinase/Protein kinase B (PI3K/Akt) and extracellular signal-regulated
kinases (ERK 1/2) signaling pathways [24]. PI3K/Akt and ERK 1/2 signaling pathways are the two
primary pathways involved in regulating cell proliferation, cell cycle, and apoptosis. Activation and
function of both pathways are under the tight control of multistep signaling control mechanisms. A
significant number of tumor cells (e.g., 41% of all melanomas) show some form of mutation in either
PI3K/Akt or ERK signaling. Currently, the PI3K/Akt and ERK signaling pathways are among the most
significant molecular targets for cancer therapy. Drugs that inhibit one of the activation steps of these
pathways prevent cancer cell proliferation and trigger cell death. Ferrocenyl pyrazoles are reported
to inhibit PI3K/Akt and ERK 1/2 signaling pathways in cancerous Michigan Cancer Foundation-7
(MCF-7). Ferrocenyl pyrazoles are also reported to cause membrane blebbing in MCF-7 breast cancer
cells. The same researchers reported that nontumorigenic MCF-10F cells do not show membrane
blebbing or inhibition of PI3K/Akt and ERK 1/2 signaling pathways when treated with ferrocenyl
pyrazoles under the same conditions [24]. We recommend investigating the effects of the compounds
used in this project on PI3K/Akt and ERK 1/2 signaling pathways on two different cell lines.
Similarly, Kim and his colleagues [25] reported that some phenylpyrazolodiazepin-7-one
derivatives prevent cell proliferation in tumorigenic cells via selective Raf kinases inhibitor activity.
Raf is the key activator of the ERK pathway, which is deregulated in one-third of all human cancers.
Raf kinase activates the Raf protein causing the activation of the ERK pathway. Therefore, Raf kinase
inhibitors are molecular targets for cancer drug development. Kim et al. also reported [25] that
1H-pyrazole-3-yl-amide derivatives reduce cell viability in several human cell lines by inhibition of
cyclin-dependent kinases [26]. Cyclin-dependent kinase controls cell cycle by phosphorylating proteins
directly involved in cell division. Mutations in cyclin-dependent kinases lead to cancer by promoting

Molecules 2020, 25, 900
8 of 20
uncontrolled cell proliferation. Drugs that inhibit cyclin-dependent kinase activity prevent cancer cells
from dividing. We recommend investigating the effects of the compounds used in this project on Raf
kinase and on cyclin-dependent kinases.
2.4.2. Cell Migration Assay
A wound-healing assay was performed to investigate whether the compounds inhibit the migration
and invasion capabilities of human keratinocytes. Cell migration was evaluated by measuring the
invasion of an artificial wound by the cells (Figure 4). To distinguish wound healing via cell proliferation
from wound healing via cell migration, cells were kept in a serum-free medium containing 2
µg/mL
colcemid starting 24 h prior to treatment. Cells were treated with 1 M (micromolar) compound. This
µ
concentration was chosen because none of the compounds showed a cytotoxic effect on A431 and
HaCaT cell at this concentration. The control group received only vehicle (0.1% DMSO). An image at
time zero was taken as a baseline, immediately after the artificial scratch wounds were created. The
wound closure was monitored over a 24-h period. Time-lapsed images of scratch wounds were taken
every two hours, starting at a time point of 12 h after the wounds were created. The percent of cell
migration was calculated and compared in cancerous vs. noncancerous keratinocytes and also between
the control and treatment groups.
Compound 3e prevented cell migration of cancerous and noncancerous keratinocytes (p < 0.05).
In the noncancerous HaCaT cell line, there was a 30% decrease in the control wound area 12 h after the
treatment. This stayed relatively stable over the 24-h periods. The treatment group showed no wound
closure for 22 h following the treatment. However, when the cells were stained, they were washed
away from the wells; therefore, no measurements were made at 24 hours following the treatment (T24).
Because compound 3e prevents the migration of cancerous cells, it should be further investigated for
its ability to reduce cancer metastasis (Figure 4a). Compound 3f inhibited the migration of cancerous
A431 keratinocytes (p < 0.05) for the first 18 h, whereas it caused an increase in the migration of
noncancerous HaCaT cell line (p > 0.05) after 12 h of treatment. We were not able to photograph this
group after 24 h of treatment. Cells detached entirely from the wells when they were treated with cold
methanol for staining.
Compound 3h caused a decrease in relative cell invasion, both in cancerous and noncancerous
keratinocytes (p < 0.05). The change in the pattern was similar, both in cancerous and noncancerous
cell lines; however, the difference between the control and treatment groups was higher in cancerous
A431 cells. Compound 3f prevented the migration of A431 cells by 60% when compared to control
cells (p < 0.05). Because compound 3f reduced the migration of cancerous cells without causing a
significant change to noncancerous cell behavior, it should be further investigated for its ability to
reduce cancer metastasis (Figure 4b).
Compound 5a caused a decrease in relative cell invasion both in cancerous and noncancerous
keratinocytes (p < 0.05). An 8% reduction in cell migration in the noncancerous cell line (p < 0.05)
and a 13% reduction in the migration of cancerous cells (p < 0.05) were observed. Both the reduction
in cell migration and the difference between the migration of cancerous and noncancerous cell lines
were found to be statistically significant (p < 0.05). Similar to compound 5a, compound 5b caused
a decrease in relative cell invasion in cancerous keratinocytes (p < 0.05). However, it did not cause
any change to the cell migration pattern of control or treatment groups in HaCaT cell lines. Twenty
hours after wounds were created, about 32% of wound closure was observed in the control group,
and 33% closure was observed in the treatment group of the HaCaT cells. However, in cancerous
A431 cells, 20 h after wounds were created, about 88% of wound closure was observed in the control
cells, whereas about 69% of wound closure was observed in the treatment group (p < 0.05). This
19% reduction in cell migration by the compound 5b was statistically significant (p < 0.05). Because
both compounds 5a and 5b reduced the migration of cancerous cells, especially 5a, without causing a
change to noncancerous cell behavior, they should be further investigated for their ability to reduce
cancer metastasis (Figure 4c,d).

Molecules 2020, 25, 900
9 of 20
Figure 4. Cont.

Molecules 2020, 25, 900
10 of 20
Figure 4. The effect of compounds (a) 3e, (b) 3h, (c) 5a, (d) 5b, (e) 5c, and (f) 5d on cell migration of
cancerous A431 vs. noncancerous HaCaT keratinocytes.
The control group and treatment groups for compounds 5c and 5d caused a time-dependent
increase in the amounts of cells that migrated to the center of the wound for the control and treatment
groups of both cancerous and noncancerous cell lines (Figure 4e,f). However, the changes were
not statistically significant (p > 0.05). Previous research has reported that diaryl urea compounds
inhibit p38 MAP kinase, which is a protein that is activated in response to cellular stress. When
activated, p38 MAP kinase causes the activation of several transcription factors. Changes to the
activity of p38 are shown to lead to an excessively high activity of transcription factor nuclear factor

Molecules 2020, 25, 900
11 of 20
kappa-light-chain-enhancer of activated B cells (NF-
κ
B), which coordinates cell survival and death [27].
Abnormalities in NF-κB activity are reported to cause cancer, as well as activation of genes that promote
cancer cell metastasis [28]. Therefore, chemicals that can inhibit p38 protein are possible therapeutic
agents. We recommend testing the effects of the compounds studied in this research on the viability of
cells, and cell migration may be a result of the interaction with p38 protein.
2.4.3. Preventing Cell Death Caused by Hydrogen Peroxide
Our data showed that all of the nine compounds studied in this project had a hormetic effect
on either one or both cell lines. Hormesis is the biphasic dose response against various agents. The
typical hormetic effect is characterized by stimulation or the increase in cell viability when exposed
to a low dose followed by an inhibitory or cytotoxic effect on cell viability when exposed to a higher
dose [29]. Even though the mechanisms behind hormesis are not well understood, several researchers
have reported that the antioxidant activity of various compounds could cause hormetic effects [30–32].
Because pyrazoles are known to have a high antioxidant activity, the antioxidant capacity of the
compounds was examined by investigating their ability to prevent cell death caused by H2O2. Because
HaCaT cells and A431 cells are reportedly strongly resistant to the effects of H2O2 [33], a relatively
high dose of H2O2 was used in these experiments. Our data showed that compounds 3e, 3f, 3g, and
5a prevented H2O2-induced cell death in noncancerous HaCaT cell lines (p < 0.05), whereas only 3f
prevented the H2O2-induced cell death in A431 cell lines (p < 0.05) (Figure 5). We did not investigate the
mechanism behind the protection from H2O2. Because exogenously applied H2O2 induces cell death in
human cells via intracellular superoxide (O2-) generation [34], we speculate that these compounds
could prevent H2O2-induced cell death via their antioxidant capacity.
Figure 5. H2O2-induced cell death protective effects of compounds (a) in cancerous A431 and (b) in
noncancerous HaCaT cell lines.
3. Materials and Methods
3.1. Materials and Physical Measurements
All of the reactants were used as purchased from Alfa Aesar (Heysham, Lancashire, UK), Merck
(Darmstadt, Germany), Sigma-Aldrich (St. Louis, MO, USA), and Fluka (Mexico City, MO, USA)
and all solvents were used without further purifications. The water content of DMF was less than
0.1%. All of the obtained products were purified by column chromatography, using silica gel 60
(0.063–1.100 mm). The melting points were determined in open glass capillaries in the Electrothermal
IA9200 melting point apparatus (Staffordshire, UK) and were uncorrected. A Shimadzu Affınity-1 FTIR
spectrophotometer (Duisburg, F.R. Germany) was used to record IR spectra using the attenuated total
reflectance (ATR) method. The 1H-NMR spectra were recorded in a Varian Mercury-400 (Seattle, WA,
USA), 400 MHz, while 13C NMR spectra were recorded in a Varian Mercury-400, 100 MHz in DMSO-d6,
and CDCl3 as a solvent. Mass spectra were obtained on a 3200 QTrap-AB Sciex LC-MS/MS spectrometer

Molecules 2020, 25, 900
12 of 20
(Darmstadt, Germany). Carbon, hydrogen, and nitrogen were estimated in a PerkinElmer 2400 Series II
CHNS/O Elemental Analyzer (Seattle, WA, USA). The results of the elemental analyses (Table S1) and
the LC-MS/MS spectra (Figures S28–S36) were all consistent with their respective molecular formulas.
All of the reactions were monitored by thin-layer chromatography (TLC) on precoated silica gel 60 F254
aluminum sheets (Merck); spots were visualized under UV light at 254 nm.
3.2. Synthesis of Compounds
3.2.1. Synthesis of 5-Pyrazolone Compounds (3a–c) Obtained from Phenylhydrazine
The 17 mmol of the appropriate β-ketoester was reacted with 14 mmol of phenylhydrazine and 5
mL of glacial acetic acid. It was refluxed in an oil bath. After the reaction was complete, the mixture
was evaporated. The remaining oily residue was solidified in an ice bath by the addition of cold diethyl
ether or hexane (20 mL). The solids were filtered through Gooch crucible and were passed 2–3 times
through cold ether. Then column chromatography was performed.
The 3-methyl-1-phenyl-1H-pyrazole-5(4H)-one (3a). This compound was synthesized according to the
general procedure using 17 mmol (2.21 g) of ethyl acetoacetate and 14 mmol (1.51 g) of phenylhydrazine
in 5 mL of glacial acetic acid by refluxing for 6 h. SiO2; n-hexane/ethyl acetate 2:1- Retention factor
(Rf): 0.16. The resulting solids were recrystallized in the benzene-petroleum ether (1:3) and collected
by filtration to give 0.999 g (41%) as a white solid, Melting point (mp): 127–130 ◦C ([
Compounds (3a ) were synthesized according to the literature [
], and their FTIR, and 1H and 13
NMR spectra corresponded to the previously reported data.
9
], 127–129 ◦C).
–
c
9
C
The 3-isopropyl-1-phenyl-1H-pyrazole-5(4H)-one (3b). This compound was synthesized according
to the general procedure using 17 mmol (2.50 g) of methyl isobutyrylacetate and 14 mmol (1.51 g) of
phenylhydrazine in 5 mL of glacial acetic acid by refluxing for 12 h. SiO2; n-hexane/ethyl acetate 2:1-
Rf: 0.29. The solid was recrystallized from benzene-petroleum ether (1:3). White solid, yield: 0.991 g
(35%), mp: 100–101 ◦C ([9]; 101–103 ◦C).
The 1,3-diphenyl-1H-pyrazole-5(4H)-one (3c). This compound was synthesized according to
the general procedure using 17 mmol (3.41 g) of ethyl benzoylacetate and 14 mmol (1.51 g) of
phenylhydrazine in 5 mL of glacial acetic acid by refluxing for 8 h. SiO2; n-hexane/ethyl acetate 2:1- Rf:
0.32. The solid was recrystallized from benzene. White solid, yield: 0.153 g (61%), mp: 137–139 ◦C ([
136–138 ◦C).
9];
The 3-(4-nitrophenyl)-1-phenyl-1H-pyrazole-5(4H)-one (3d). 10 mmol (2.3 g) ethyl 4-nitrobenzoyl
acetate, 10 mmol (1.4 mL) phenylhydrazine, and 10 mL glacial acetic acid were refluxed in an oil bath
for 5 h. After the reaction was complete, the mixture was evaporated. The residue was dissolved
in ethyl acetate (20 mL) and extracted with saturated NaHCO3 (2
×
10 mL). The organic phase was
re-extracted with saturated brine, then dried with Na2SO4, and the solvent was then evaporated. Then
column chromatography was performed (SiO2; n-hexane/ethyl acetate 2:1- Rf: 0.22). The solid was
recrystallized from ethanol, and collected by filtration to give 1.096 g (39%) as a yellow solid, mp:
188–191 ◦C ([12]; 190–191 ◦C). Compound 3d was synthesized according to the literature [12], and its
FTIR, and 1H and 13C NMR spectra corresponded to the previously reported data.
3.2.2. Synthesis of 5-Pyrazolone Compounds (3e–g) Derived from Phenylhydrazine Hydrochloride
The 5 mmol of β-keto ester, 5 mmol of an appropriately substituted phenylhydrazine hydrochloride
in 10 mL of absolute methyl alcohol were refluxed in an oil bath (reaction times: For 3e 8h, for 3f 16 h,
for 3g 12 h). After the reaction was complete, the mixture was evaporated. The residue was purified
by using column chromatography (5:2 petroleum ether: ethyl acetate).
The 5-hydroxy-3-(4-nitrophenyl)-1-(p-tolyl)-1H-pyrazole (3e). The title compound was synthesized
according to the general procedure using 5 mmol (1.19 g) of ethyl 4-nitrobenzoyl acetate and 5 mmol
(0.81 g) of p-tolylhydrazine hydrochloride. SiO2; petroleum ether/ethyl acetate 5:2- Rf: 0.32. Yellow
solid, yield: 0.797 g (54%), mp: 220–221 ◦C. Elemental analysis; calculated for C16H13N3O3; C, 65.08; H,

Molecules 2020, 25, 900
13 of 20
4.44; N, 14.23; found: C, 64.97; H, 4.54; N, 14.17. IR (ATR, cm-1): 3093, 2924, 2850, 2615–2441 (enolic
OH), 1562 (C=N), 1415, 1350 (NO2) 1381, 1238, 1145, 1111, 1076, 1018, 964, 852, 744. The 1H-NMR
(400 MHz, DMSO-d6):
nitrophenyl C , J = 8.8 Hz), 7.71(d, 2H, phenyl C
6.20 (s, 2H, pyrazolone C ,), 2.35 (s, 3H, -C
3). The 13C-NMR (100 MHz, DMSO-d6,):
pyrazolone), 147.7, 147, 140.4, 136.6, 136.1, 129.9 (2xAr H), 124.5 (2xAr H), 126.3 (2x Ar
(2xAr CH), 86.5 (C4 pyrazolone), 21 (-CH3). LC-MS/MS m/z 294.4 [M-1]+, 295.4 [M]+.
δ
12.01(s, 1H, -O
H
), 8.28 (d, 2H, nitrophenyl C
H
, J = 8.8 Hz), 8.10 (d, 2H,
, J = 8.4 Hz),
154.5 ( =O
H), 121.9
H
H
, J = 8.4 Hz), 7.32 (d, 2H, phenyl C
H
δ
H
H
C
C
C
C
The 1-(4-bromophenyl)-3-(4-nitrophenyl)-1H-pyrazole-5(4H)-one (3f). The title compound was
synthesized according to the general procedure using 5 mmol (1.19 g) of ethyl 4-nitrobenzoyl acetate
and 5 mmol (1.12 g) of 4-bromophenylhydrazine hydrochloride. SiO2; petroleum ether /ethyl acetate
5:2- Rf: 0.12. Yellow solid, yield: 0.450 g (25%), mp: 182–183 ◦C. Elemental analysis; calculated for
C15H10BrN3O3: C, 50.02; H, 2.80; N, 11.67; found: C, 49.86; H, 2.83; N, 11.55. IR (ATR, cm-1): 3105, 2920,
2850, 1705 (C=O), 1589–1485 (C=N & C=C), 1338 (-NO2), 1315, 1296, 1157, 1122, 1068, 1002, 952, 821,
748 (C-Br). The 1H-NMR (400 MHz, CDCl3):
2H, nitrophenyl C ), 7.89 (d, J:9.2 Hz, 2H, bromophenyl C
3.92 (s, 2H, pyrazolone C
). The 13C-NMR (100 MHz, CDCl3,):
132.0 (2xAr H), 126.7 (2xAr H), 124.3 (2xAr H), 120.5, 118.8 (2xAr
m/z 359.9 [M]+, 361.4 [M+2]+.
δ
8.36 (d, J:9.2 Hz, 2H, nitrophenyl C
H
), 7.97 (d, J:8.8 Hz,
),
=O), 152.5, 148.9, 136.8, 136.2,
H), 39.32 (- H3). LC-MS/MS
H
H
), 7.56 (d, J: 9.2 Hz, 2H, bromophenyl CH
H
δ
169.7 (
C
C
C
C
C
C
The 1-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazole-5(4H)-one (3g). The title compound was
synthesized according to the general procedure using 5 mmol (1.19 g) of ethyl 4-nitrobenzoyl acetate
and 5 mmol (0.91 g) of 4-chlorophenylhydrazine hydrochloride. SiO2; petroleum ether/ethyl acetate
5:2- Rf: 0.2. Orange solid, yield: 1.105 g (70%), mp: 185–186 ◦C. Elemental analysis; calculated for
C15H10ClN3O3: C, 57.07; H, 3.19; N, 13.87; found: C, 56.79; H, 3.29; N, 13.87. IR (ATR, cm-1): 3093, 2916,
2850, 1705 (C=O), 1593–1485 (C=N & C=C), 1340 (-NO2), 1315, 1276, 1157, 1122, 1087, 1006, 952, 825,
748 (C-Cl). The 1H-NMR (400 MHz, CDCl3):
2H, chlorophenyl C ), 7.94 (d, J: 3.2 Hz, 2H, chlorophenyl C
3.92 (s, 2H, pyrazolone C
). The 13C-NMR (100 MHz, CDCl3):
131, 129.1 (2xAr H), 126.7 (2xAr H), 124.3 (2xAr H), 120.2 (2xAr
314.2 [M-1]+; 316.2 [M+1]+.
δ
8.36 (d, J: 9.2 Hz, 2H, nitrophenyl C
), 7.41 (d, J: 3.2 Hz, 2H, nitrophenyl C
, 169.7 ( =O), 152.4, 148.9, 136.3, 136.2,
H), 39.3 (-CH3). LC-MS/MS m/z
H
), 7.97 (d, J: 8.8 Hz,
H
H
H
),
H
δ
C
C
C
C
C
The 1-(4-bromophenyl)-3-methyl-1H-pyrazole-5(4H)-one (3h). The 2.25 mmol (0.3 mL) of ethyl
acetoacetate and 3 mmol (0.7 g) of 4-bromophenylhydrazine hydrochloride in 5 mL of absolute ethanol
were allowed to stir at room temperature for 24 h. After the reaction was complete, the mixture was
evaporated. The residue was purified by using column chromatography. SiO2; petroleum ether/ethyl
acetate 5:2- Rf: 0.18. Cream solid, yield: 0.308 g (54%), mp: 170–172 ◦C ([13]; yellow oily compound).
Elemental analysis; calculated for C10H9BrN2O: C, 47.46; H, 3.58; N, 11.07; found: C, 47.54; H, 3.54; N,
11.14. IR (ATR, cm-1): 3051, 2916, 2850, 2681–2522 (enolic OH), 1610, 1581, 1400 (C=N & C=C), 1361,
1330, 1222, 1149, 1076, 1006, 750, 624, 574 (C-Br). The 1H-NMR (400 MHz, CDCl3):
Hz, 2H, Ar C ), 7.50 (d, J =8.8 Hz, 2H, Ar C ), 3.42 (s, 2H, pyrazolone C ), 2.22 (s, 3H, -C
13C-NMR (100 MHz, CDCl3):
170.5 ( =O), 156.6, 137.2, 131.8 (2 Ar H), 120.2, 117.8 (2
43.1 (-CH2), 17.1 (-CH3). LC-MS/MS m/z 251 [M]+; 253 [M+2]+.
δ
7.82 (d, J =9.2
3). The
Ar H),
H
H
H
H
×
δ
C
×
C
C
3.2.3. General Procedure for the Preparation of 4-Formyl-2-Pyrazoline-5-One (4a–d)
In a round flask, 1.15 mmol of pyrazolone was dissolved in 2 mL of DMF. After cooling to 0 ◦C in
an ice bath, 1.28 mmol (0.12 mL) phosphoryl chloride (POCl3) was added dropwise for 15 min while
the temperature remained between 0–20 ◦C. After the addition was complete, the reaction mixture was
heated in water vapor at 85 ◦C for 1.5 h. After the reaction was completed, 10 mL of the ice–water
mixture was poured into the room-temperature mixture. The reaction mixture was stirred overnight.
The aqueous mixture was extracted with chloroform (3
solvent was evaporated. The solids were crystallized in ethanol.
×
10 mL), then dried with Na2SO4, and the

Molecules 2020, 25, 900
14 of 20
The 3-Methyl-1-phenyl-4-formyl-2-pyrazoline-5-one (4a). It was synthesized according to the literature.
Yellow solid, yield: 0.116 g (50%), mp: 177–179 ◦C ([35]; 175–176 ◦C). Compounds 4a and 4b were
synthesized according to the literature [35], and their FTIR, and 1H and 13C NMR spectra corresponded
to the previously reported data.
The 3-Isopropyl-1-phenyl-4-formyl-2-pyrazoline-5-one (4b). It was synthesized according to the
literature. Yellow solid, yield: 1.266 g (55%), mp: 155–157 ◦C ([35] 149–150 ◦C).
The 1,3-diphenyl-4-formyl-2-pyrazoline-5-one (4c). It was synthesized according to the literature.
Yellow solid, yield: 0.499 g (45%), mp: 146–147 ◦C (According◦to the literature, when this product
is crystallized from naphtha, the melting point is 146.5–148.5 C, and when it is crystallized from
2-methoxyethanol again, the melting point increases to 248–249 ◦C.) [36]. Compound 4c was synthesized
according to the literature [36], and its FTIR, and 1H and 13C NMR spectra corresponded to the previously
reported data.
The 5-hydroxy-3- (4-nitrophenyl) -1-phenyl-4-formyl-1H-pyrazole (4d). The 1.4 mmol (0.4 g) of
compound 3d was placed on a round 25-mL capacity flask and dissolved in 1 mL of DMF then cooled
in ice to 0 ◦C. Then, 0.5 mL (5.4 mmol) of POCl3 was added dropwise for 15 min while the temperature
was maintained between 0–20 ◦C. After the addition was complete, the reaction mixture was heated in
water vapor at 85 ◦C for 3 h. After the reaction was completed, 10 mL of iced water was poured into
the room-temperature mixture. The reaction mixture was stirred overnight. The aqueous mixture was
extracted with dichloromethane (3
×
10 mL), then dried with Na2SO4, and the solvent was evaporated.
Purification by silica gel column chromatography (petroleum ether/ethyl acetate 5:2) gave compound
4d as an orange solid. The solid was recrystallized from ethanol, and collected by filtration to give
0.195 g (45%), as an orange solid, mp: 272–273 ◦C. Elemental analysis; calculated for C16H11N3O4: C,
62.14; H, 3.59; N, 13.59; found: C, 62.06; H, 3.50; N, 13.65. IR (ATR, cm-1): 3066, 2978, 2850, 2800, and
2742 (aldehyde CH), 1670 (C=O), 1597 (C=N), 1315 (-NO2), 1489, 1292, 1126, 1095, 1029. The 1H-NMR
(400 MHz, CDCl3):
(d, J:8.4 Hz, 2H, nitrophenyl C
150.9, 148.3, 137.2, 136.7, 135.7, 129.9 (2
Ar CH), 116.8. LC-MS/MS m/z 308.2 [M−1]+.
δ
10.10 (s, 1H, -C
), 7.66–7.61 (m, 5H, Ar C
Ar H), 129.8 (2
H
O), 9.90 (s, 1H, -O
H
), 8.34 (d, J: 8.4 Hz, 2H, nitrophenyl C
H
H
), 8.19
183,
H), 123.6 (2
H
). The 13C-NMR (100 MHz, CDCl3,):
Ar H), 129.5, 125.4 (2 Ar
δ
×
C
×
C
×
C
×
3.2.4. General Procedure for the Preparation of Urea-5-Pyrazolones (5a–d)
After 1 mmol of the compound 4-formyl-2-pyrazoline-5-one was dissolved in 10 mL of DMF, 10
mmol of urea was added to the mixture. The reaction mixture was heated at 85 ◦C in an oil bath for 6 h.
After the reaction was completed, 20 mL of bi-distilled water was added to the mixture and allowed to
stir for 10 min. The aqueous mixture was removed by extraction in chloroform (3
Na2SO4, and the solvent was evaporated. The solids were purified by column chromatography (5:2
petroleum ether: ethyl acetate).
×
10 mL), dried with
N-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)methyl]urea (5a). SiO2; petroleum
ether/ethyl acetate 5:2- Rf: 0.52. Yellow solid, yield: 0.068 g (28%), mp: 230–232 ◦C (lit23; 228–229 ◦C).
Elemental analysis; calculated for C12H12N4O2: C, 59.01; H, 4.95; N, 22.94; found: C, 58.93; H, 4.81; N,
23.07. IR (ATR, cm-1): 3348, 3278 (-NH2), 3201 (-NH), 3062, 1735 (C=O), 1670 (C=O), 1597 (C=N), 1558,
1489, 1377, 1253, 1161, 1045. The 1H-NMR (400 MHz, DMSO-d6):
12 Hz, urea-C =C), 7.94 (d, J: 7.6 Hz, 2H, Ar C ), 7.79 (s, 2H, -N
(t, J: 14.8 Hz, H, Ar C ), 2.24 (s, 3H, -C
3). The 13C-NMR (100 MHz, DMSO-d6):
H), 124.5, 118.1(2xAr H), 104.8, 12,9 (-
H3). LC-MS/MS: m/z 243.2 [M-1]+;
δ
10.8 (d, J:12.4 Hz, -N
2), 7.41 (t, J: 16 Hz, 2H, Ar C
164.5, 153.1, 150.3,
H
), 8,21 (d, J:
H
H
H
H
), 7.15
H
H
δ
143.5, 139.2, 129.3(2xAr
244.3 [M]+.
C
C
C
N-[(1,5-dihydro-1-phenyl-5-oxo-3-(isopropyl)-4H-pyrazol-4-ylidene)methyl]urea (5b). SiO2; petroleum
ether /ethyl acetate 5:2- Rf: 0.16. Yellow solid, yield: 0.089 g (33%), mp: 179–181 ◦C. Elemental analysis;
calculated for C14H16N4O2: C, 61.75; H, 5.92; N, 20.58; found: C, 61.88; H, 5.86; N, 20.77. IR (ATR,
cm−1): 3340–3270 (-NH2), 3190 (-NH), 3062, 2970, 2873, 1701 (C=O), 1662 (C=O), 1577 (C=N), 1489,
1377, 1253, 1161, 1014. The 1H-NMR (400 MHz, DMSO-d6):
δ 10.87 (d, J: 12 Hz, 1H, -NH), 8.25 (d, J:12

Molecules 2020, 25, 900
15 of 20
Hz, 1H, -C
14.8 Hz, 1H, Ar C
DMSO-d6): 164.8 (
26.8 (-CH), 21.6 (-CH(CH3)2). LC-MS/MS: m/z 271.2 [M-1]+ 272.9 [M]+.
H
=C), 7.97 (d, J: 7.6 Hz, 2H, Ar C
), 3.11 (m, 1H, -C ), 1.26 (d, J: 7.2 Hz, 6H,-CH(C
=O), 157.8 ( =O), 143, 139.2, 129.3 (2 Ar H), 124.6, 118.2 (2
H
), 7.85 (s, 2H, -N
H
2), 7.42 (t, J:16 Hz, 2H, Ar C
H
), 7.16 (t, J:
H
H
H
3)2). The 13C-NMR (100 MHz,
δ
C
C
×
C
×
Ar CH), 103.2,
N-[(1,5-dihydro-1,3-diphenyl-5-oxo-4H-pyrazol-4-ylidene)methyl]urea (5c). SiO2; petroleum ether/ethyl
acetate 5:2- Rf: 0.2. Yellow solid, yield: 0.110 g (36%), mp: 220–223 ◦C. Elemental analysis; calculated
for C17H14N4O2: C, 66.66; H, 4.61; N, 18.29; found: C, 66.90; H, 4.50; N, 18.50. IR (ATR, cm-1): 3421,
3278 (-NH2), 3201 (-NH), 3059, 1759 (C=O), 1658 (C=O), 1597 (C=N), 1477, 1373, 1265, 1172, 1111. The
1H-NMR (400 MHz, DMSO-d6):
(d, J: 8 Hz, 2H, Ar C ), 7.88 (s, 2H, -N
(t, J: 14.4 Hz, 1H, Ar C
). The 13C-NMR (100 MHz, DMSO-d6):
139, 131.4, 130.1 (2 Ar H), 129.5 (2 Ar H), 129.4, 128.1 (2
102.7. LC-MS/MS: m/z 305.2 [M-1]+ 306.5 [M]+.
N-[(1,5-Dihydro-1-phenyl-5-oxo-3-(4-nitrophenyl)-4H-pyrazol-4-ylidene)methyl]urea (5d).
petroleum ether/ethyl acetate 5:2- Rf: 0.08. Orange solid, yield: 0.109 g (31%), mp: >250 C
decomposition. Elemental analysis; calculated for C17H13N5O4: C, 58.12; H, 3.73; N, 19.93; found: C,
58.26; H, 3.70; N, 20.16. IR (ATR, cm−1): 3294–3124 (-NH2 & -NH), 3051, 1662 (C=O), 1643 (C=O), 1597
δ
11.11 (d, J: 12.4 Hz, 1H, -N
2), 7.75 (d, J: 7.6 Hz, 2H, Ar C
164.8(
Ar
H
), 8.31 (d, J: 12.4 Hz, 1H, -C
), 7.55–7.47 (m, 5H, Ar C
=O), 152.9 ( =O), 150.9, 145.2,
H), 125.1, 118.7 (2 Ar H),
H
=C), 8.06
H
H
H
H
), 7.22
H
δ
C
C
C
×
C
×
C
×
×
C
SiO2;
◦
(C=N), 1512, 1381, 1195, 1103, 1323 (-NO2). The 1H-NMR (400 MHz, DMSO-d6):
1H, -N ), 9.47 (s, 2H, -N 2), 8.34 (d, J: 8.8 Hz, 2H, nitrophenyl C
-C =C), 8.09 (d, J: 8.4 Hz, 2H, Ar C ), 8.03 (d, J: 8.8 Hz, 2H, nitrophenyl C
), 7.19 (t, J: 14.8 Hz, 1H, Ar C
). The 13C-NMR (100 MHz, DMSO-d6):
147.8, 147.7, 139.5, 138.8, 129.2 (2 Ar H), 12 8.9 (2 Ar H), 124.4 (2
δ
, 9.69 (d, J: 14.8 Hz,
), 8.21–8.15 (dd, J1: 8.4, J2: 8 Hz 1H,
), 7.45 (t, J:16 Hz, 2H, Ar
165.8 ( =O), 154.9 ( =O),
Ar H), 118.8 (2 Ar H),
H
H
H
H
H
H
H
C
H
×
δ
C
C
C
C
×
C
×
C
×
97.3. LC-MS/ MS: m/z 353.4 [M+2]+ 374.6 [M+Na]+.
3.3. Biological Assays
3.3.1. Cell Cultures
Human skin cancer cell lines A431 (highly invasive, metastatic) and HaCaT (noncancerous,
immortalized) were maintained as a monolayer culture in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented by 10% fetal bovine serum (FBS). Gentamicin and fungizone were added to prevent
◦
contamination. Cell cultures were kept in a CO2 incubator at 37 C under 5% CO2. Cells were
subcultured every third day (1:10 ratio). For subcultures, cells were rinsed with Trypsin containing
ethylenediaminetetraacetic acid (Trypsin-EDTA) after the cell culture medium was removed. After 5
min of incubation in Trypsin-EDTA at 37 ◦C, cells were dislodged by gentle aspiration. The cells were
transferred into a 15 mL conical tube and centrifuged at 200 g for 2 min. The pellet was resuspended
×
in a minimal volume of complete growth medium (37 ◦C). After determining the total number of cells
and percent viability using the Countess® Automated Cell Counter (Invitrogen, Grand Island, NY,
USA), growth media was added to achieve the required cell concentration. Cells then were diluted to
the seeding density in a new cell culture flask. The flasks were returned the cells to the incubator.
3.3.2. Cell Viability Assay
Human cancerous A431 and HaCaT keratinocytes were seeded in 96-well plates (5000 cells per
well) and incubated in standard cell culture medium overnight. Compounds were dissolved in DMSO
to prepare a 10 mM stock solution and were further diluted in cell culture medium to prepare the
treatment doses. The following day, the culture medium was removed, and the cells were treated
with 0.0001, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, and 1 mM compound for each chemical for 24, 48, 72, and
96 h. The control group was treated with DMSO (0.1% of the total culture volume). At the end of the
corresponding treatment time, MTT dye (5 mg/mL, Sigma, St. Louis, MO, U.S.A.) was added to each
well, and cells were incubated in a cell culture incubator. After 4 h of incubation in MTT, the medium
was removed, and formazan crystals were dissolved in 100 µl of DMSO (Sigma, USA). Optical density

Molecules 2020, 25, 900
16 of 20
was measured at 570 nm wavelength on a microplate reader. The following Equation (1) was used to
determine the percentage cell viability:
Asample
Cell Viability (%) =
× 100
(1)
Acontrol
The effects of the compounds on cell viability of cancerous and noncancerous cell lines were
compared by using the General Linear Model. To minimize the effect of chance variance and improve
accuracy, all experiments were performed in triplicates for each condition and were repeated twice.
3.3.3. Cell Migration Assay
A straight line was drawn to the bottom of 12-well plates by using an ultra-fine Sharpie. HaCaT
and A431 cells were seeded in marked 12-well plates in a serum-free medium containing 2 µM colcemid
to 80% confluence. After overnight incubation, two scratch wounds per well were made by scraping the
cell monolayer by using a p2 pipet tip. Wells were washed with 37 ◦C phosphate buffered saline (PBS)
three times. Two mL of the medium containing 1 µM (micromolar) of the corresponding compound and
2 µM colcemid was added onto the cells. Cells were visualized and photographed under a microscope
to confirm the formation of the scratch wound. After 12 h of incubation in the 37 ◦C incubator, cells
were removed from the incubator, and wounds were photographed every two hours for the following
12-h period. At T24, the medium was aspirated from the wells, and the cells were fixed with 0.5 mL of
ice-cold methanol at
20 ◦C for 10 min. Following this, methanol was aspirated from the plates, and
−
0.5 mL of crystal violet solution was added onto the cells. The cells were incubated with crystal violet
at room temperature for 10 min. At the end of 10 min, the stain was removed and the cells were rinsed
4–5 times in deionized water. Plates were dried at room temperature, and images were taken under a
10x objective. The area of cell migration over time was quantified using ImageJ software. To minimize
the effect of chance variance and improve accuracy, all experiments were performed in triplicate wells
for each condition. Four images at the intersection of scratch wounds and premarked lines were taken
per well. The migration distance was calculated based on the width of the wounds. The widths of the
12 areas were averaged per compound. The average for each compound was normalized to its control
wells. The effects of the compounds on cell migration of cancerous and noncancerous cell lines were
compared by using the General Linear Model.
3.3.4. Effects of Compounds on H2O2-Induced Cytotoxicity
The antioxidant potential of the compounds was investigated by measuring the ability of the
compounds to prevent H2O2-induced cell death. The 96-well plates were seeded with A431 and HaCaT
cells with each well containing 5000 cells/well. After overnight incubation, the standard cell culture
medium was replaced with the medium that contained a 10
µM compound. After 24 h incubation in
the compounds, half of the cells were treated with 10 M H2O2. The control group was treated with
µ
DMSO (0.1% of the total culture volume). At the end of two-hour treatment with H2O2, MTT dye (5
mg/mL, Sigma, St. Louis, MO, U.S.A.) was added to each well, and cells were incubated in cell culture
incubator for 4 h. Following this, the medium was removed, and formazan crystals were dissolved in
100 µl of DMSO (Sigma, St. Louis, MO, U.S.A.). Optical density was measured at 570 nm wavelength
on a microplate reader. Equation (1) was used to determine the percentage of cell viability. The effects
of the compounds on cell viability of the cancerous and noncancerous cell lines were compared by
using the General Linear Model. To minimize the effect of chance variance and improve accuracy, all
experiments were performed in triplicates for each condition.

Molecules 2020, 25, 900
17 of 20
3.4. Statistical Analysis
Statistical analyses of the effects of compounds on cell viability, cell migration, and antioxidant
capacity were determined using a General Linear Model (SPSS v26). For the cell viability with four time
points as a within-subject factor, cancer versus no cancer cell lines as a between-subjects factor, and
dose (vehicle plus seven concentrations) as another between-subjects factor (a 4
design. For the cell migration assay with seven time points as a within-subject factor, cancer versus
no cancer cell lines as a between-subjects factor, and dose (vehicle plus one concentration) as another
×
2
×
8 mixed factor)
between-subjects factor (a 7
presence of H2O2 as a within-subject factor, cancer versus no cancer cell lines as a between-subjects
×
2
×
2 mixed factor) design. For the antioxidant capacity assay with the
factor, and dose (vehicle plus one concentration) as another between-subjects factor (a 2
factor design).
×
2
×
2 mixed
4. Conclusions
The synthesis part of our study consisted of three stages. In the first step, three new
substitutes 5-pyrazolone were synthesized by condensation of 4-substituted phenylhydrazines
with suitable
β-keto esters. Subsequently, the carbon 4 of the pyrazolone ring was formulated
to form the corresponding pyrazolone ring aldehydes. In the last stage, pyrazolone-CH=NCONH2
tautomerized by condensation of 4-carbaldehyde-5-pyrazolone compounds with urea yielded four new
substituted-pyrazole-4-ylidenemethylurea compounds in the form of pyrazolone=CH-NHCONH2.
The structures of the nine new compounds were characterized by elemental analysis, FTIR, 1H and
13C NMR, and LC/MS-MS spectroscopic methods. In contrast, the in vitro biological potentials were
evaluated by biological tests such as MTT, cell migration, and prevention of H2O2-induced cell death.
To evaluate the toxicity of the compounds on cancerous cells, both cancerous and noncancerous
cells that were derived from the same tissue (tumorigenic A431 skin cancer cells and nontumorigenic
HaCaT human keratinocytes) were studied simultaneously. When the efficacy of the compounds on
cell viability was examined by MTT test, all compounds containing urea (5a–d) showed higher toxicity
in cancerous A431 cells compared to noncancerous cells at all time points (p < 0.05). In particular, 1 mM
5a decreased cell viability by approximately 90% in both A431 and HaCaT cells after 24 h of treatment
(p < 0.05). Because of the lower toxicity of compounds 3e, 3f, 3h, and 5a–d to noncancerous cells, it
requires further investigation of their pharmacological potential. Compounds 4d and 3g showed high
toxicity to cancer-free cells; therefore, their effects on cell migration were not investigated.
By using cell scratch (wound healing) assay, we investigated whether the compounds inhibit the
migration and invasion ability of human keratinocytes. Compound 3e
to inhibit cell migration of cancerous keratinocytes (p < 0.05). In particular, the ability of 3e
,
3f
,
5a, and 5b were observed
5a
,
,
and 5b to reduce cancer metastasis, as it prevents migration of cancerous cells, since it increases the
migration of cancer-free cells, was observed. Compound 3f needs to be further investigated for its
wound-healing capabilities.
To investigate the antioxidant capacity of the compounds, their ability to prevent cell death caused
by H2O2 was investigated. However, four of the nine compounds prevented cell death caused by
H2O2. The antioxidant capacity and the effects of these compounds on necrosis and apoptosis will be
further investigated in future studies.
Our data show that some of these compounds have the potential to be considered as promising
useful building blocks of drug design investigations that prevent cancer metastasis and promote
wound healing. In addition, because the urea end of the pyrazolone ring has the potential to undergo
different chemical modifications, we speculate that this ability may help these structures to exhibit
additional pharmacological activities.

Molecules 2020, 25, 900
18 of 20
Supplementary Materials: The following are available online. Figure S1–S9: The FTIR spectra of the synthesized
compounds. Figure S10–18: The 1H-NMR spectra of the synthesized compounds. Figures S19–S27: The 13C NMR
spectra of the synthesized compounds. Figure S28–S36: The LC-MS/MS spectra of the synthesized compounds.
Figure S37–S45: The time-dependent cell viability plots. Figure S46: The time- and dose-dependent cell viability
plots. Table S1: The elemental analysis results of the synthesized compounds.
Author Contributions: A.G.E. conceived, designed the experiment, and wrote the paper. H.O. performed the
experiment and analyzed the data. All authors have read and agreed to the published version of the manuscript.
Funding: This work was financially supported by Ordu University Scientific Research Project Coordination
Department (ODU-BAP), Ordu, TURKEY (grant No. AR-1511).
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Chmutova, G.A.; Kataeva, O.N.; Ahlbrecht, H.; Kurbangalieva, A.R.; Movchan, A.I.; Lenstra, A.T.H.;
Geise, H.J.; Litvinov, I.A. Derivatives of 1-phenyl-3-methylpyrazol-2-in-5-thione and their oxygen analogues
in the crystalline phase and their tautomeric transformations in solutions and in the gas phase. J. Mol. Struct.
2001, 570, 215–223.
2.
3.
4.
5.
6.
Al-Mutairi, A.A.; El-Baih, F.E.M.; Al-Hazimi, H. Microwave versus ultrasound assisted synthesis of some
new heterocycles based on pyrazolone moiety. J. Saudi Chem. Soc. 2010, 14, 287–299. [CrossRef]
Mojtahedi, M.M.; Javadpour, M.; Abaee, M.S. Convenient ultrasound mediated synthesis of substituted
pyrazolones under solvent-free conditions. Ultrason. Sonochem. 2008, 15, 828–832. [CrossRef] [PubMed]
Heise, H.; Hintzmann, M. Pyrazolone derivatives. In Ullmann’s Encycloprdia of Industrial Chemistry;
Wiley-VCH, Ed.; Wiley-VCH: Weinheim, Germany, 2010; Volume 30, p. 547.
Pal, S.; Mareddy, J.; Devi, N.S. High speed synthesis of pyrazolones using microwave-assisted neat reaction
technology. J. Braz. Chem. Soc. 2008, 19, 1207–1214. [CrossRef]
Dube, P.N.; Bule, S.S.; Mokale, S.N.; Kumbhare, M.R.; Dighe, P.R.; Ushir, Y.V. Synthesis and biologic evaluation
of substituted 5-methyl-2-phenyl-1H-pyrazol-3(2H)-one derivatives as selective COX-2 inhibitors: Molecular
docking study. Chem. Biol. Drug Des. 2014, 84, 409–419. [CrossRef]
7.
8.
9.
Khan, R.; Md. Uddin, I.; Md. Alam, S.; Hossain, M.M.; Md. Islam, R. Synthesis and preliminary evaluation
of brominated 5-methyl-2,4-dihydropyrazol-3-one and its derivatives as cytotoxic agents. Bangladesh J
Pharmacol. 2008, 3, 27–35.
Ragab, F.A.F.; Abdel-Gawad, N.M.; Georgey, H.H.; Said, M.F. Pyrazolone derivatives: Synthesis,
anti-inflammatory, analgesic, quantitative structure–activity relationship and in vitro studies. Chem. Pharm.
Bull. 2013, 61, 834–845. [CrossRef]
Huang, Y.Y.; Lin, H.C.; Cheng, K.M.; Su, W.N.; Sung, K.C.; Lin, T.P.; Huang, J.J.; Lin, S.K.; Wong, F.F. Efficient
di-bromination of 5-pyrazolones and 5-hydroxypyrazoles by N-bromobenzamide. Tetrahedron 2009, 65,
9592–9597. [CrossRef]
10. Jing, L.; Wang, L.; Zhao, Y.; Tan, R.; Xing, X.; Liu, T.; Huang, W.; Luo, Y.; Li, Z. Synthesis, crystal structure
and evaluation of cancer inhibitory activity of 4-[indol-3-yl-methylene]-1H-pyrazol-5(4H)-one derivatives. J.
Chem. Res. 2012, 36, 691–696. [CrossRef]
11. Sheng, X.; Hua, K.; Yang, C.; Wang, X.; Ji, H.; Xu, J.; Huang, Z.; Zhang, Y. Novel hybrids of 3-n-butylphthalide
and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. Bioorg. Med.
Chem. Lett. 2015, 25, 3535–3540. [CrossRef]
12. Nakagawa, H.; Ohyama, R.; Kimata, A.; Suzuki, T.; Miyata, N. Hydroxyl radical scavenging by edaravone
derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base.
Bioorg. Med. Chem. Lett. 2006, 16, 5939–5942. [CrossRef] [PubMed]
13. Štefane, B.; Polanc, S. Aminolysis of 2,2-difluoro-4-alkoxy-1,3,2-dioxaborinanes: Route to β-keto amides and
β-enamino carboxamides. Tetrahedron 2007, 63, 10902–10913. [CrossRef]
14. Porai-Koshits, B.A.; Kvitko, I.Y.; Shutkotva, E.A.; Galkina, T.M. Aminomethylene derivatives of azoles. VI.
Hydrolysis product of aminomethylene derivatives of 1-phenyl-3-methyl-5-pyrazolone. Zh. Obshch. Khim.
1966, 2, 174–177.

Molecules 2020, 25, 900
19 of 20
15. Hawkes, G.E.; Randall, E.W.; Elguero, J.; Marzin, C.J. Proton, carbon-13, and nitrogen-15
nuclear magnetic resonance studies of [15N]azoles: 1-phenylpyrazole and the tautomerically mobile
3-methyl-1-phenylpyrazolin-5-one. J. Chem. Soc. Perkin Trans. 1977, 8, 1024–1027. [CrossRef]
16. Elguero, J.; Martíanez, A.; Singh, S.P.; Grover, M.; Tarar, L.S.A. 1H and 13C NMR study of the structure and
tautomerism of 4-pyrazolylpyrazolinones. J. Heterocycl. Chem. 1990, 27, 865–870. [CrossRef]
17. Evans, N.A.; Whelan, J.; Johns, R.B. Tautomerism in the 5-pyrazolone series: 1(H)-5-pyrazolones and
indazolones. Tetrahedron 1965, 21, 3351–3361. [CrossRef]
18. Amarasekara,
tautomerism
A.S.;
of
Owereh,
4-acylpyrazolone
O.;
Lyssenko,
Schiff bases
K.A.;
Timofeeva,
crystal
T.V.
structure
Structural
of
and
5-methyl-2-phenyl-4-{1-[(pyridin-2-ylmethyl)-amino]-ethylidene}-2,4-dihydro-pyrazol-3-one. J. Struct. Chem.
2009, 50, 1159–1165. [CrossRef]
19. Liou, G.Y.; Storz, P. Reactive oxygen species in cancer. Free Radic. Res. 2010, 44, 479–496. [CrossRef]
20.
H
ájková, A.; Barek, J.; Vyskocˇil, V. Electrochemical DNA biosensor for detection of DNA damage induced by
hydroxyl radicals. Bioelectrochemistry 2017, 116, 1–9. [CrossRef]
21. Asadi, N.S.; Heidari, M.M.; Khatami, M. Protective effect of Berberis vulgaris on Fenton reaction-induced
DNA cleavage. Avicenna J. Phytomed. 2019, 9, 213–220.
22. Markovic’, V.; Eric
´
, S.; Stanojkovic , T.; Gligorijevic
´
´, N.; Aran-delovic´, S.; Todorovic´, N.; Trifunovic´, S.;
Manojlovic , N.; Jelic
´
´
, R.; Joksovic´, M.D. Antiproliferative activity and QSAR studies of a series of new
4-aminomethylidene derivatives of some pyrazol-5-ones. Bioorg. Med. Chem. Lett. 2011, 21, 4416–4421.
[CrossRef] [PubMed]
23. Kasiotis, K.M.; Tzanetou, E.N.; Haroutounian, S.A. Pyrazoles as potential anti-angiogenesis agents: A
contemporary overview. Front. Chem. 2014, 2, 78. [CrossRef] [PubMed]
24. Atmaca, H.; Özkan, A.N.; Zora, M. Novel ferrocenyl pyrazoles inhibit breast cancer cell viability via
induction of apoptosis and inhibition of PI3K/Akt and ERK1/2 signaling. Chem. Biol. Interact. 2017, 263,
28–35. [CrossRef] [PubMed]
25. Kim, H.; Kim, M.; Lee, J.; Yu, H.; Hah, J.M. Syntheses of phenylpyrazolodiazepin-7-ones as conformationally
rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. Bioorg. Med.
Chem. 2011, 22, 6760–6767. [CrossRef] [PubMed]
26. Pevarello, P.; Brasca, M.G.; Orsini, P.; Traquandi, G.; Longo, A.; Nesi, M.; Orzi, F.; Piutti, C.; Sansonna, P.;
Varasi, M. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. J. Med.
Chem. 2005, 8, 2944–2956. [CrossRef] [PubMed]
27. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. CSH Perspect Biol. 2009, 1, a001651.
28. Xia, Y.; Shen, S.; Verma, I.M. NF-κB, an active player in human cancers. Cancer Immunol. Res. 2014, 2, 823–830.
[CrossRef]
29. Mattson, M.P. Hormesis defined. Ageing Res. Rev. 2008, 7, 1–7. [CrossRef]
30. Mattson, M.P. Dietary factors, hormesis and health. Ageing Res. Rev. 2008, 7, 43–48. [CrossRef]
31. Calabrese, V.; Cornelius, C.; Trovato-Salinaro, A.; Cambria, M.T.; Locascio, M.S.; Rienzo, L.D.; Calabrese, E.J.
The hormetic role of dietary antioxidants in free radical-related diseases. Curr. Pharm. 2010, 16, 877–883.
[CrossRef]
32. Maher, J.; Yamamoto, M. The rise of antioxidant signaling-the evolution and hormetic actions of Nrf2. Toxicol.
Appl. Pharm. 2010, 244, 4–15. [CrossRef] [PubMed]
33. Zhang, T.; Woods, T.L.; Elder, J.T. Differential responses of S100A2 to oxidative stress and increased
intracellular calcium in normal, immortalized, and malignant human keratinocytes. J. Invest. Dermatol. 2002
,
119, 1196–1201. [CrossRef] [PubMed]
34. Tochigi, M.; Inoue, T.; Suzuki-Karasaki, M.; Ochiai, T.; Ra, C.; Suzuki-Karasaki, Y. Hydrogen peroxide induces
cell death in human TRAIL-resistant melanoma through intracellular superoxide generation. Int. J. Oncol.
2013, 42, 863–872. [CrossRef] [PubMed]
35. Huang, Y.Y.; Kaneko, K.; Takayama, H.; Kimura, M.; Wong, F.F. New investigation of Vilsmeier-type reaction
using pyrazolones with various amides. Tetrahedron Lett. 2011, 52, 3786–3792. [CrossRef]

Molecules 2020, 25, 900
20 of 20
36. Wallace, D.J.; Straley, J.M. Synthesis of 5-oxo-2-pyrazoline-4-carboxaldehydes. J. Org. Chem. 1961, 26,
3825–3826. [CrossRef]
Sample Availability: Samples of the compounds are not available from the authors.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).